Milestone Pharmaceuticals (MIST) AI Stock Analysis

• Market Cap: $96.52M
• Dividend Yield: N/A
• Average Volume (3M): 1.17M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.40
• Revenue Growth: -100.00%
• EPS Growth: 35.07%
• Country: US
• Employees: 47
• Sector: Healthcare
• Sector Strength: 78
• Industry: Biotechnology
• EPS (TTM): -0.90
• Shares Outstanding: 53,327,908
• 10 Day Avg. Volume: 1,565,125
• 30 Day Avg. Volume: 1,171,880
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 96.52
• Price to Cash Flow (P/CF): -3.40
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $13.00
• Price Target Upside: 540.39% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3

Milestone Pharmaceuticals faces significant financial challenges with no revenue generation and high leverage. However, the potential launch of CARDAMYST presents a transformative opportunity. Despite mixed technical indicators and poor valuation metrics, this event could significantly alter the company's future trajectory if successful.

Positive Factors

Commercial Launch

Milestone is well-positioned for a successful commercial launch, which should unlock substantial value for shareholders.

Product Safety and Usability

CARDAMYST's favorable safety profile and ease of use in the at-home setting anticipates multiple use cases by patients.

Negative Factors

Financial Performance

MIST reported a net loss of $9.4MM in the third quarter.

Milestone Pharmaceuticals Business Overview & Revenue Model

Company Description

Milestone Pharmaceuticals Inc. (MIST) is a biopharmaceutical company primarily operating in the healthcare sector, focusing on the development and commercialization of innovative cardiovascular medicines. The company is committed to providing effective treatment solutions for patients with episodic cardiovascular conditions. Its core product is etripamil, a novel, fast-acting nasal spray designed for the acute treatment of paroxysmal supraventricular tachycardia (PSVT) and other cardiovascular indications.

How the Company Makes Money

Milestone Pharmaceuticals generates revenue through the development and commercialization of its pharmaceutical products, primarily etripamil. The company aims to secure regulatory approvals and bring its products to market, targeting healthcare providers and institutions as its primary customers. Revenue streams are expected from product sales, potential partnerships, and licensing agreements with larger pharmaceutical companies that may include upfront payments, milestones, and royalties. Additionally, strategic collaborations and partnerships can enhance its market reach and provide funding to support further research and development efforts, contributing to its overall earnings.

Milestone Pharmaceuticals Financial Statement Overview

Summary

The company's financial performance is weak, with significant negative profitability, high leverage, and poor cash flow efficiency. The income statement, balance sheet, and cash flow scores reflect severe financial challenges, including declining revenues, increasing debt, and operational inefficiencies.

Income Statement

The income statement reveals severe challenges with consistently negative net income and declining revenue, particularly the TTM (Trailing-Twelve-Months) showing negative revenue. The gross profit margin and net profit margin are significantly negative due to the lack of positive revenue and high operational expenses. The EBIT and EBITDA margins are also deeply negative, indicating operational inefficiencies.

Balance Sheet

The balance sheet highlights a precarious financial position with a high debt-to-equity ratio of 2.25 in the TTM, indicating significant leverage. Stockholders' equity has decreased, and the equity ratio has been declining, reflecting a shrinking financial cushion. The return on equity is negative, showing that the company is not generating profits from shareholders' investments.

Cash Flow

The cash flow statement shows negative free cash flow with no signs of improvement, as indicated by the negative free cash flow growth rate in the TTM. Operating cash flow is also negative, and both the operating and free cash flow to net income ratios indicate inefficiencies in converting operational activities into cash.

Breakdown
TTM	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
-868.00K	1.00M	5.00M	15.00M	0.00	0.00
	Gross Profit
-1.45M	1.00M	4.52M	15.00M	-376.00K	-236.00K
	EBIT
-43.70M	-61.10M	-59.64M	-43.07M	-50.71M	-57.88M
	EBITDA
-38.84M	-56.84M	-58.36M	-42.98M	-50.71M	-57.88M
	Net Income Common Stockholders
-42.77M	-59.69M	-57.13M	-42.63M	-49.97M	-55.23M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
66.00M	66.00M	64.58M	114.14M	142.31M	119.82M
	Total Assets
75.23M	75.23M	74.48M	119.85M	149.97M	123.43M
	Total Debt
51.77M	51.77M	2.49M	698.00K	941.00K	514.00K
	Net Debt
38.02M	38.02M	-5.14M	-113.44M	-71.37M	-119.30M
	Total Liabilities
58.45M	58.45M	8.13M	7.25M	6.86M	8.51M
	Stockholders Equity
16.77M	16.77M	66.35M	112.60M	143.12M	114.92M
Cash Flow		Free Cash Flow
-31.27M	-46.54M	-52.74M	-33.22M	-50.73M	-51.56M
	Operating Cash Flow
-31.12M	-46.42M	-52.47M	-33.22M	-50.73M	-51.15M
	Investing Cash Flow
2.50M	4.76M	-57.12M	70.00M	-70.00M	-384.00K
	Financing Cash Flow
32.32M	47.79M	3.09M	5.05M	73.22M	85.41M

Milestone Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2.03
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MIST, the sentiment is Positive. The current price of 2.03 is above the 20-day moving average (MA) of 1.92, above the 50-day MA of 2.02, and above the 200-day MA of 1.67, indicating a bullish trend. The MACD of -0.04 indicates Negative momentum. The RSI at 55.14 is Neutral, neither overbought nor oversold. The STOCH value of 65.34 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for MIST.

Milestone Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
XERS	66 Neutral	$703.51M	―	222.83%	―	23.89%	16.86%
ARQT	54 Neutral	$1.84B	―	-113.76%	―	229.74%	70.23%
EOLS	54 Neutral	$853.33M	―	-913.07%	―	31.76%	24.85%
Sector *	49 Neutral	$6.84B	0.05	-53.14%	2.48%	24.49%	-3.26%
MIST	45 Neutral	$96.52M	―	-162.87%	―	-100.00%	35.07%
BCRX	45 Neutral	$1.58B	―	18.68%	―	36.00%	63.50%
VTGN	42 Neutral	$80.53M	―	-46.28%	―	-33.00%	54.91%

Milestone Pharmaceuticals Corporate Events

Milestone Pharmaceuticals Prepares for CARDAMYST Launch

On February 25, 2025, Milestone Pharmaceuticals announced its preparation for the potential launch of CARDAMYST, a nasal spray containing etripamil, pending FDA approval. The company anticipates a significant impact on its operations with the expected approval and commercial launch in mid-2025, which could extend its patent estate to 2042 and provide a $75 million payment upon approval. This development is seen as transformative for Milestone, potentially reducing healthcare costs and empowering patients by providing a new therapeutic option.